@article{article, title  = {{A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2013}},

 month = {{5}},

 author = {{Talbot DC and Blackhall FH and Kowalski D and Ramlau R and Bepler G and Grossi F and Lerchenmuller CA and Pinder MC and Mezger J and Danson S and Callies S et al}},

 doi = {{10.1200/jco.2013.31.15_suppl.8051}},

 volume = {{31}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{8051-8051}},

 note = {{Accessed on 2025/01/13}}}